Is Athersys stem cell therapy a real option for severe COVID-19? Learn how it targets acute respiratory distress, safety concerns, evidence so far, and what to ask before considering investigational cell therapy abroad.
Athersys stem cell therapy, using multipotent adult progenitor cells (MAPC), is being tested as a potential supportive treatment for severe COVID-19—especially for patients experiencing acute respiratory distress syndrome (ARDS), a major cause of critical illness and death. Current research suggests stem cell approaches may help modulate inflammation in the lungs, but results are mixed and long-term benefit is still under investigation. This treatment is not a guaranteed cure, nor is it approved as standard care for COVID-19 anywhere in 2026.
For families facing severe COVID-19, especially when standard options are exhausted, the need for alternatives is urgent and deeply personal. Many search for therapies that might limit ventilator time or reduce risk of organ failure. Headlines about Athersys and similar cell therapies have raised hopes, but also questions: What is really proven? Is it safe to try? Are these treatments legal or available outside clinical trials?
In severe COVID-19, the body’s immune system can overreact, flooding the lungs with inflammatory cells and fluid. This can trigger a cascade called ARDS—acute respiratory distress syndrome—where air sacs become stiff and oxygen transfer is impaired. Roughly 40–60% of patients with full-blown ARDS die, even with intensive care. The main cause of death isn’t just the virus—it’s the overwhelming, uncontrolled inflammation damaging lung tissue.
Athersys’s MAPC stem cells are designed to be given intravenously and may home to areas of injury by responding to molecular signals in inflamed lung tissue. These cells release anti-inflammatory signals—such as TGF-β (transforming growth factor beta), VEGF (vascular endothelial growth factor), and other immune-regulating molecules—through a process called paracrine signalling (chemical messages that influence nearby cells). The goal isn’t to replace damaged cells, but to calm the immune response, limit scarring, and support tissue repair.
Early-phase clinical trials since 2020 have tested Athersys’s MultiStem (MAPC) product in ARDS, including patients with severe COVID-19. Some pilot studies reported trends towards lower mortality and improved ventilator-free days, but others did not reach statistical significance. A 2021 phase II/III trial failed to meet its primary outcome for COVID-19 ARDS, but some subgroups—especially younger patients—may have seen modest benefit. Safety signals were generally acceptable, but numbers are still small.
Other clinical trials have used MSCs—often from umbilical cord tissue—rather than Athersys’s proprietary MAPC platform. Results again are mixed: some studies show improvement in oxygen levels and inflammatory markers, but others report no clear difference in survival. Safety data for MSCs in severe viral lung injury is generally favourable, but long-term follow-up is still ongoing for COVID-19–specific applications.
No stem cell therapy—including Athersys, MSCs, or exosomes—is established as a standard, reimbursed treatment for COVID-19 or ARDS in any major country as of 2026. Some studies show potential signals of benefit, but others do not. There is no proven way to guarantee survival or recovery with these methods, and no guideline yet recommends their routine use for COVID-19.
Investigational stem cell therapies for COVID-19 ARDS are reserved for patients whose standard treatment options are failing—typically those in intensive care, often ventilated, and not improving with all evidence-based supportive measures. Candidacy is determined case by case in a clinical trial or by special request at regulated centers abroad. Not every patient is eligible, and conditions like active cancer, severe organ failure, or advanced age may exclude participation.
In regulated clinics like ours in Istanbul, the pathway for investigational stem cell therapy involves: advanced pre-treatment assessment (including existing diagnosis, medical history, imaging, and lab results); multi-disciplinary eligibility review; development of a personalised protocol; hospital-based administration (often intravenous infusion); and structured monitoring before, during, and after the intervention. Non-Turkish international patients are treated under our clinic’s international protocol with TİTCK oversight—no individual Ministry of Health permit is required per patient. Turkish citizens require Sağlık Bakanlığı approval for cell therapy treatments.
At our Istanbul clinic, all cell therapies use ethically donated, umbilical cord-derived MSCs or other approved products, processed under GMP standards, cryopreserved at -196°C, and rigorously screened for infections (HIV, HBV, HCV, CMV, EBV), mycoplasma, endotoxins, and cell identity (CD73, CD90, CD105). All protocols are supervised by experienced physicians and align with TİTCK (Turkish Medicines and Medical Devices Agency) requirements. No cells are administered without laboratory release documentation.
Expectations must be grounded in evidence and patient context. Most published data show at best a potential for supporting recovery—typically as a modest increase in ventilator-free days or lower inflammatory markers in select subgroups. Results vary: some may experience a change within weeks, others may see no effect. Functional gains (breathing unaided, quicker ICU discharge) are possible but are not guaranteed. For many, changes—if any—appear slowly and require continued standard care.
Stem cell and progenitor cell therapies are generally well tolerated, but infusion reactions (fever, shortness of breath, allergic response), infection risk, and, rarely, thromboembolic events have been reported. There is always a risk of treatment not working, and delays in standard care can be dangerous. Cell therapy for severe viral lung injury is not a miracle solution and should only be considered where all conventional therapies have been tried—or as part of a regulated research protocol.
You are considering a treatment that is not routinely available or reimbursed in your home country. That does not mean it is illegal for you to receive it abroad. It means the treatment must be understood under Turkish medical regulation, not under the approval or reimbursement rules of your home country. Our clinic coordinates care for international patients—including English-speaking team support, transfer arrangements, and post-treatment communication. Not every patient is eligible. Each case is carefully reviewed for medical appropriateness and regulatory compliance.
No country recognized by the World Health Organization has approved Athersys’s MultiStem or any stem cell product as standard treatment for COVID-19. Use remains investigational or possible under specific clinical trial or compassionate access frameworks.
Early studies have shown stem cell treatments are generally well tolerated, but critically ill patients have higher risks of adverse events. No therapy is risk-free. Infusion reactions, infection, and, rarely, blood clotting complications have been reported.
No. There are no guarantees of benefit or cure. Some studies report improved ventilator-free days, but others show no significant difference compared to standard care. It should be viewed as a potential supportive measure, not a cure.
Yes—international patients may access investigational stem cell treatments in regulated Turkish clinics under TİTCK oversight, provided all eligibility and legal standards are met. Turkish citizens require an additional Ministry of Health permit. Always clarify your eligibility with the clinic directly.
Most evidence suggests potential benefit, if any, is highest when stem cell therapy is given early in the course of ARDS—typically within the first several days of respiratory failure. Delayed treatment may not show the same effect.
Likely not as part of their standard protocols—stem cell therapy for COVID-19 is investigational in most countries. However, your treating team should be informed if you pursue this route, and all reports or documentation should be shared for coordinated care.
Immediate return to conventional medical management is critical if there is any deterioration. Investigational cell therapy is never a replacement for emergency care, resuscitation, or intensive hospital support.
Athersys’s MultiStem and similar products are regulated as investigational biologics or advanced therapies—such as IND status in the US, or under ATMP frameworks in the EU. Legal status may differ in Turkey, where therapies are permitted under Ministry of Health/TİTCK regulations for eligible patients.
Choosing investigational cell therapy for severe COVID-19 is rarely a simple decision. The most responsible path is an individual, physician-led evaluation looking at your whole clinical picture, regulatory settings, practical needs, and what the science actually supports. If you or your loved one may be a candidate, our clinic offers a Free Consultation for medical history review, eligibility assessment, and structured discussion of risks and expectations—no high-pressure tactics, no outcome promises. Clarity and safety first.
Athersys Stem Cell Therapy for COVID-19: What Does the Evidence Say?